Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Signaling Pathways and Emerging Therapies in Multiple Myeloma. Curr Hematol Malig Rep 2016 Apr;11(2):156-64

Date

02/29/2016

Pubmed ID

26922744

DOI

10.1007/s11899-016-0315-4

Scopus ID

2-s2.0-84962224784   9 Citations

Abstract

Multiple myeloma (MM) is a devastating malignancy of antibody-producing plasma cells. In the absence of a single unifying genetic event contributing to disease manifestation, efforts have focused on understanding signaling events deregulated in myeloma plasma cells. MM cells are dependent on both cellular and non-cellular components of the tumor microenvironment such as bone marrow stromal cells, endothelial cells, and cytokines such as interleukin 6 (IL6), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF) for their growth and survival. The cumulative effect of such interactions is the aberrant activation of numerous signal transduction pathways within the MM plasma cells leading to uncontrolled growth and prevention of apoptosis. Here, we will review our current understanding of some of the key signal transduction pathways dysregulated in MM and emerging therapies targeting these pathways in MM.

Author List

Ramakrishnan V, D'Souza A

Author

Anita D'Souza MD Associate Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Animals
Antineoplastic Agents
Humans
Multiple Myeloma
NF-kappa B
Proto-Oncogene Proteins c-akt
Signal Transduction
TOR Serine-Threonine Kinases
jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a